Annexon (NASDAQ:ANNX) EVP Sells $31,747.50 in Stock

by · The Cerbat Gem

Annexon, Inc. (NASDAQ:ANNX – Get Free Report) EVP Michael Overdorf sold 6,225 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total value of $31,747.50. Following the completion of the sale, the executive vice president directly owned 124,464 shares of the company’s stock, valued at $634,766.40. The trade was a 4.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Annexon Price Performance

Annexon stock traded down $0.20 during mid-day trading on Friday, reaching $4.90. 1,749,100 shares of the company traded hands, compared to its average volume of 2,388,556. Annexon, Inc. has a 52-week low of $1.28 and a 52-week high of $7.18. The firm has a market capitalization of $586.19 million, a price-to-earnings ratio of -3.48 and a beta of 1.17. The firm’s 50 day moving average price is $5.58 and its 200 day moving average price is $3.93.

Hedge Funds Weigh In On Annexon

Several large investors have recently made changes to their positions in the business. Invesco Ltd. grew its stake in shares of Annexon by 381.5% in the 4th quarter. Invesco Ltd. now owns 972,449 shares of the company’s stock worth $4,882,000 after buying an additional 770,504 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in Annexon during the fourth quarter valued at $52,000. XTX Topco Ltd boosted its holdings in Annexon by 64.6% in the fourth quarter. XTX Topco Ltd now owns 243,313 shares of the company’s stock worth $1,221,000 after acquiring an additional 95,473 shares in the last quarter. Ikarian Capital LLC purchased a new stake in shares of Annexon in the fourth quarter worth $1,156,000. Finally, Virtus Investment Advisers LLC increased its holdings in shares of Annexon by 27.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 53,527 shares of the company’s stock valued at $269,000 after acquiring an additional 11,540 shares in the last quarter.

Wall Street Analyst Weigh In

ANNX has been the subject of a number of research reports. Wells Fargo & Company increased their price target on shares of Annexon from $14.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Finally, Chardan Capital started coverage on Annexon in a research report on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Annexon has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Check Out Our Latest Report on ANNX

About Annexon

(Get Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.

Further Reading